<DOC>
	<DOCNO>NCT01070784</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy Symbicort Turbuhaler compare standard COPD treatment one year Japanese patient COPD .</brief_summary>
	<brief_title>A Safety Efficacy Study Symbicort Turbuhaler Compared With Standard Chronic Obstructive Pulmonary Disease ( COPD ) Treatment Japan</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Budesonide , Formoterol Fumarate Drug Combination</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<criteria>A current clinical diagnosis COPD accord guideline ( GOLD , JPS ) Documented COPD symptom 2 year Prebronchodilator FEV1≦50 % predict normal value , postbronchodilator FEV1/FVC＜70 % History and/or current clinical diagnosis asthma atopic diseases allergic rhinitis Subjects significant unstable ischemic heart disease , arrhythmia , cardiomyopathy , heart failure , uncontrolled hypertension define investigator , relevant cardiovascular disorder judge investigator COPD exacerbation runin period within 4 week prior registration , require hospitalization and/or treatment systemic steroid .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Symbicort</keyword>
	<keyword>Safety</keyword>
	<keyword>Efficacy</keyword>
	<keyword>COPD</keyword>
	<keyword>Japanese</keyword>
</DOC>